“…10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes – 2020 [55] Aspirin therapy (75–162 mg/day) may be considered as a primary prevention strategy in those with diabetes who are at increased CV risk, after a comprehensive discussion with the patient on the benefits versus the comparable increased risk of bleeding | | A | | 2016 European guidelines on CVD prevention in clinical practice [29] | Antiplatelet therapy is not recommended for people with DM who do not have CVD | III | A | 107 |
2021 ESC guidelines on cardiovascular disease prevention in clinical practice [8] | In patients with DM at high or very high CVD risk, low dose aspirin may be considered for primary prevention in the absence of clear contraindications | IIb | A | 3, 43, 108 |
2020 Società Italiane di Cardiologica e Società Italiane di Diabetologia joint document [57] | - Antiplatelet therapy is not recommended for people with DM who do not have CVD
- In diabetic patients with multiple risk factors for ASCVD, aspirin use in primary prevention must be evaluated on an individual basis after accurate clinical judgment
| I I | B C | 1, 43, 105, 109–115 |
Guideline for prevention and treatment of type 2 diabetes in China (2020 edition) [58] | Aspirin therapy as a primary prevention strategy can be recommended in diabetic patients with high CVD risk; that is, those aged ≥50 years with at least one additional major risk factor (family history of premature ASCVD, hypertension, dyslipidemia, smoking, or CKD/albuminuria) without high bleeding risk | IIb | Not provided | 3, 4, 5, 11, 43, 52, 58, 86, 116 |
2019 Clinical practice guidelines for type 2 diabetes mellitus in Korea [ 66 ] | Aspirin (100 mg daily) may be considered for primary prevention in patients with DM at high CV risk, if they do not have high bleeding risk | IIb | C | 52 |
ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; DAPT, dual antiplatelet therapy; DM, diabetes mellitus; GI, gastrointestinal; PPI, proton pump inhibitor. …”